Tandem Diabetes snags FDA approval for interoperable insulin pump software
Tandem Diabetes’ technology will create a new approval pathway for predictive dosing software that can be used with other devices.
New Abbott diabetes deal is a “missed opportunity” for DexCom
Abbott struck a deal with Bigfoot Medical by which the latter will use Abbott's glucose sensing technology to develop an artificial pancreas and not that of DexCom, the CGM market leader.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA approves first artificial pancreas much sooner than expected
FDA approves the first automated insulin delivery system giving Medtronic the distinction of being the first in a category that is set to revolutionize daily disease management for type 1 diabetes patients.
Insulet takes another step closer to introduce artificial pancreas
The tubeless insulin pump maker enrolls first patients in feasibility study to tests it artificial pancreas technology.
Bigfoot Biomedical’s artificial pancreas is emerging from hack mode with a $15M Series A in the works
Bigfoot Biomedical is building an artificial pancreas, combining continuous glucose monitor tech with an insulin pump - and raising some capital to do so.
The world’s first artificial pancreas goes to a 4-year-old boy in Australia
A 4-year-old boy in Australia, Xavier Hames, just received the first artificial pancreas device from Princess Margaret Hospital for Children, which will regulate his insulin levels for him. The hospital was where clinical trials for the device have been taking place for several years, and now it’s available for $8,100. This is big news for the many […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership
San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process. As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial […]